Humus Capital Partners
Humus Capital Partners LLC is a private equity firm based in Buenos Aires, Argentina, focusing on middle market and emerging growth investments. Established in 2009, the firm specializes in industry consolidation, buyouts, turnarounds, and growth capital investments, primarily within sectors such as animal protein, frozen foods, hospitality and leisure, education, healthcare, and retail, particularly in Latin America. Humus Capital Partners aims to invest approximately $20 million in its portfolio companies, typically seeking a majority stake and taking a seat on the board of directors. The firm plans to exit its investments through initial public offerings or sales to strategic buyers while avoiding investments in the land and agriculture sectors.
Top Stages
https://crunchbase.com/organization/***
https://linkedin.com/company/***
2 past transactions
Aaktei Management
Private Equity Round in 2019
Aaktei Management develops renewable energy projects in Chile covering all stages from conceptual idea to construction and COD.
Biosidus
Private Equity Round in 2018
Biosidus S.A., founded in 1983 and headquartered in Buenos Aires, Argentina, is a leading biotechnology company specializing in the development, manufacture, and supply of biosimilars. The company's product portfolio includes eight therapeutic proteins, such as Epoetin for chronic renal failure, Filgrastim for cancer treatment, Somatropin for growth hormone deficiency, and Lenograstim for various conditions. Biosidus also has a robust pipeline of therapeutic proteins at different stages of development, including retuximab and etanercept product candidates. The company operates two manufacturing plants: the Almagro Plant for research and development and production of pharmaceutical active ingredients, and the Bernal Plant for aseptic filling, lyophilization, and packing. Biosidus focuses on transgenic animals and gene therapy applied to vascular disease management, with a strong intellectual property policy that provides a competitive advantage in the biosimilars market. The company has established a global business supplying high-quality biopharmaceuticals to territories in Asia, Africa, Eastern Europe, and Latin America.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.